mounjaro weight loss vs semaglutide Day 3: (Tirzepatide – weekly injection) Class: Dual GLP-1 and GIP receptor agonist Avg Loss: ~20% of baseline weight (SURMOUNT-1 trial) FDA Status: Approved for type 2 diabetes; Fast-tracked for Mounjaro vs. Wegovy: The 2026

Mice were culled by cervical dislocation

Recent surveys show more employers are starting to cover GLP-1s for obesity, even as the drugs are driving up health costs

Canadian Patents Database notes the status as: Expired and beyond the Period of Reversal. In the U.S., Novo Nordisk said in its 2025 Form 20-F that U.S

Human relevance of thyroid C-cell tumors in rats is unknown and could not be determined by clinical studies or nonclinical studies [see Boxed Warning, Warnings and Precautions (5.1)]

A holistic approach, combining GLP-1s with lifestyle interventions and enhanced medication adherence strategies, will be instrumental in addressing the multifaceted nature of these health concerns

doi: 10.1007/s00535-012-0634-8 87